The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2025 | Insights into the GOLSEEK-4 trial: golcadomide plus rituximab in R/R follicular lymphoma
Eliza Hawkes, MBBS Hons, FRACP, DMedSc, Olivia Newton-John Cancer Research Institute at Austin Health, Melbourne, Australia, briefly discusses the GOLSEEK-4 trial (NCT06911502), which is evaluating the combination of golcadomide plus rituximab in relapsed/refractory (R/R) follicular lymphoma.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Yes, so this was a trial in progress abstract that we submitted to EHA for our randomized study of golcadomide and rituximab in the relapsed setting against standard of care. And so this study is ongoing and in development and we should be opening it very soon. And this is really just testing that the golcadomide and rituximab are not just improving efficacy but also much more deliverable than some of our standard treatments that we have available for follicular lymphoma now...
Yes, so this was a trial in progress abstract that we submitted to EHA for our randomized study of golcadomide and rituximab in the relapsed setting against standard of care. And so this study is ongoing and in development and we should be opening it very soon. And this is really just testing that the golcadomide and rituximab are not just improving efficacy but also much more deliverable than some of our standard treatments that we have available for follicular lymphoma now.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
